How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

128,668 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Changes in the spatial distribution of the under-five mortality rate: Small-area analysis of 122 DHS surveys in 262 subregions of 35 countries in Africa. Full Text available with Trip Pro

Changes in the spatial distribution of the under-five mortality rate: Small-area analysis of 122 DHS surveys in 262 subregions of 35 countries in Africa. The under-five mortality rate (U5MR) is a critical and widely available population health indicator. Both the MDGs and SDGs define targets for improvement in the U5MR, and the SDGs require spatial disaggregation of indicators. We estimate trends in the U5MR for Admin-1 subnational areas using 122 DHS surveys in 35 countries in Africa (...) and assess progress toward the MDG target reductions for each subnational region and each country as a whole. In each country, direct weighted estimates of the U5MR from each survey are calculated and combined into a single estimate for each Admin-1 region across five-year periods. Our method fully accounts for the sample design of each survey. The region-time-specific estimates are smoothed using a Bayesian, space-time model that produces more precise estimates (when compared to the direct estimates

2019 PLoS ONE

22. Medium-term outcomes of converting laparoscopic adjustable gastric band to Roux-en-Y gastric bypass in patients with body mass index &lt;35 kg/m<sup>2</sup>: a uniquely Australian perspective. (Abstract)

Medium-term outcomes of converting laparoscopic adjustable gastric band to Roux-en-Y gastric bypass in patients with body mass index <35 kg/m2: a uniquely Australian perspective. The rates of primary laparoscopic adjustable gastric banding (LAGB) have declined in the last 5 years due to band removal secondary to complications and the subsequent weight regain that requires revisional procedures.This study aimed to present medium-term weight loss results and the safety profile (...) for conversion, weight loss data, and early (30 d postoperative) and late complications were recorded with follow-up out to 5 years.One hundred thirty-two adult patients with a BMI <35.0 kg/m2 underwent conversion from 2009 to 2016. The main indications for conversion were reflux and band complications. Median BMI at bypass was 32.8 kg/m2 (23.1-35.0). Median percentage excess weight loss was 77%, 90%, 73%, 47%, 49%, and 44% at 1, 2, 3, 4, and 5 years, respectively among patients who were eligible and present

2020 Surgery for Obesity and Related Diseases

23. Placental function and fetal weight are associated with maternal hemodynamic indices in uncomplicated pregnancies at 35-37 weeks of gestation. Full Text available with Trip Pro

weeks of gestation in normal pregnancies.Prospective screening of women attending Kings' College Hospital for routine hospital visit at 35-37 weeks' gestation. We recorded maternal characteristics and measured mean arterial pressure, uterine artery pulsatility index, sonographic estimated fetal weight, and serum placental growth factor and soluble fms-like tyrosine kinase 1. We also performed maternal echocardiogram to assess cardiac output and peripheral vascular resistance as well as indices (...) Placental function and fetal weight are associated with maternal hemodynamic indices in uncomplicated pregnancies at 35-37 weeks of gestation. Over the years, there has been an increasing interest in the assessment of maternal hemodynamic responses during pregnancy. With the use of both noninvasive devices and/or maternal echocardiography, it has been shown that mothers who have pregnancy complications have altered hemodynamics compared with those who have uncomplicated pregnancies. It also has

2020 American Journal of Obstetrics and Gynecology

24. Ortho-Novum 1/35

Ortho-Novum 1/35 Ortho-Novum 1/35 Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ortho-Novum 1/35 Ortho-Novum 1/35 Aka: Ortho-Novum 1 (...) /35 , Ortho Novum 1/35 , Norinyl , Norinyl 1/35 , Necon , Dasetta , Alyacen , Nortrel 1/35 , Norimin , Pirmella 1/35 II. Preparations (Norethindrone / Ethinyl Estradiol) Ortho Novum 1/35, Norinyl 1/35, Nortrel 1/35, Necon, Dasetta or Alyacen Norimin (UK) III. Components 1.0 mg (see preparations above) 35 ug IV. Effect Relative : 1.0 (moderate) : 38 (high) : 0.34 (moderate) V. Pill associated problems Indications to switch to (lower androgen) Increased Appetite (lower ) provoked (lower

2018 FP Notebook

25. Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1)

Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet Reference number: 2850 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital Llandough Penlan Road Llandough Vale of Glamorgan CF64 2XX (...) awttc@wales.nhs.uk 029 2071 6900 This report should be cited as: All Wales Therapeutics & Toxicology Centre. AWMSG Secretariat Assessment Report. Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet. Reference number: 2850. November 2018. Dolutegravir/rilpivirine (Juluca ® ). Reference number 2850. Page 1 of 14 This assessment report will be considered for review three years from the date of the Final Appraisal Recommendation. AWMSG Secretariat Assessment Report Dolutegravir

2019 All Wales Medicines Strategy Group

26. Nivolumab (melanoma): Addendum to Commission A16-35

Nivolumab (melanoma): Addendum to Commission A16-35 Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68 [Nivolumab (melanoma): Addendum to Commission A16-35] Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68 [Nivolumab (melanoma): Addendum to Commission A16-35] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68. [Nivolumab (melanoma): Addendum to Commission A16-35] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 465. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Melanoma Language Published German Country

2016 Health Technology Assessment (HTA) Database.

27. Addendum to Commission A13-35 (dabrafenib)

Addendum to Commission A13-35 (dabrafenib) 1 Translation of the addendum Addendum zum Auftrag A13-35 (Dabrafenib) (Version 1.0; Status: 14 March 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 March 2014 1.0 Commission: A14-10 Version: Status: IQWiG Reports – Commission No. A14-10 Addendum to Commission A13-35 (dabrafenib) 1 Addendum (...) – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Addendum to Commission A13-35 Version 1.0 (dabrafenib) 14 March 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - IQWiG employees involved in the dossier assessment 2 : ? Natalia Wolfram ? Christoph Schürmann ? Wiebke Sieben ? Siw Waffenschmidt ? Beate Wieseler Keywords: dabrafenib, melanoma, benefit assessment 2 Due to legal data protection regulations, employees have the right not to be named

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

28. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents

reported. No serious adverse events were treatment-related in the Symtuza ® arms and no safety concerns were identified. CHMP highlights that using tenofovir alafenamide instead of tenofovir disoproxil fumarate would offer an improved renal and bone safety profile. ? Symtuza ® reduces pill burden compared with taking the fixed-dose combinations Rezolsta ® and Descovy ® . Budget impact ? The company estimates that the eligible number of patients will be 24 in Year 1, rising to 35 patients in Year 5 (...) Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ® ). Reference number 2418. Page 1 of 3 Enc 9 Appx 2 AWMSG Secretariat Assessment Report – Limited submission Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ®? ) 800 mg/150 mg/200 mg/10 mg film-coated tablet Company: Janssen-Cilag Ltd Licensed indication under

2018 All Wales Medicines Strategy Group

29. Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35-42 years with a body weight ≥50 kg: a randomized controlled trial. Full Text available with Trip Pro

centre in Vietnam from June 2015 to August 2016. A total of 400 patients were included, 200 in each treatment group. The primary outcome measure was the number of oocytes retrieved. Patients were followed for 1 year after randomization.Participants aged 35-42 years with a body weight ≥50 kg who were undergoing an IVF cycle were randomized to undergo COS with a single dose of corifollitropin alfa 150 μg on Day 2 or 3 of the menstrual cycle, or follitropin beta 300 IU/day for 7 days starting on Day 2 (...) Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35-42 years with a body weight ≥50 kg: a randomized controlled trial. Is corifollitropin alfa 150 μg equivalent to follitropin beta 300 IU/day for controlled ovarian hyperstimulation (COS) in older women weighing ≥50 kg undergoing IVF and/or ICSI in Vietnam?Corifollitropin alfa 150 μg was equivalent to follitropin beta 300 IU/day with respect to the number of oocytes retrieved, the ongoing, cumulative

2017 Human reproduction open Controlled trial quality: predicted high

30. Cost-effectiveness study: Potential cost-savings may be considerable with management of hypertension according to updated US hypertension guidelines, but for women aged 35?44?years these benefits are unlikely

Cost-effectiveness study: Potential cost-savings may be considerable with management of hypertension according to updated US hypertension guidelines, but for women aged 35?44?years these benefits are unlikely Potential cost-savings may be considerable with management of hypertension according to updated US hypertension guidelines, but for women aged 35–44 years these benefits are unlikely | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content (...) are here Potential cost-savings may be considerable with management of hypertension according to updated US hypertension guidelines, but for women aged 35–44 years these benefits are unlikely Article Text Economic analysis Cost-effectiveness study Potential cost-savings may be considerable with management of hypertension according to updated US hypertension guidelines, but for women aged 35–44 years these benefits are unlikely Dominique A Cadilhac , Joosup Kim Statistics from Altmetric.com Commentary

2015 Evidence-Based Medicine

31. Mercury-associated glomerulonephritis: a retrospective study of 35 cases in a single Chinese center. Full Text available with Trip Pro

Mercury-associated glomerulonephritis: a retrospective study of 35 cases in a single Chinese center. Long-term exposure of mercury may induce glomerulonephritis. Clinical and pathological features of mercury-associated glomerulonephritis are not fully clear. This study retrospectively analyzed 35 cases of mercury-associated glomerulonephritis in a single Chinese center.Thirty-five patients of mercury-associated glomerulonephritis were enrolled. Clinical data on diagnosis and during follow-up (...) -two patients (62.9%) had nephrotic syndrome. Renal histopathology showed minimal change disease (MCD) in 21 patients (60.0%), MN in 13 (37.1%) and focal segmental glomerular sclerosis (FSGS) in 1 patient (2.9%). The proportion of MCD increased along with urinary mercury concentration (P = 0.024). In 13 cases of MN, all patients were negative for plasma anti-PLA2R antibody and glomerular PLA2R antigen. IgG1 (61.5%) and IgG4 (46.2%) deposits were noted along the glomerular capillary loops. Among

2019 BMC Nephrology

32. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. (Abstract)

Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. To investigate the potential value of uterine artery pulsatility index (UtA-PI) and serum levels of the angiogenic placental growth factor (PlGF) and the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) in the prediction of adverse perinatal outcome in small-for-gestational-age (SGA) and non-SGA neonates at 35-37 weeks' gestation.This was a prospective observational (...) study of 19 209 singleton pregnancies attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation. This visit included recording of maternal demographic characteristics and medical history, sonographic estimation of fetal weight, color Doppler ultrasound for measurement of mean UtA-PI, and measurement of serum concentrations of PlGF and sFlt-1. Multivariable logistic regression analysis was carried out to determine which of the factors from maternal or pregnancy characteristics

2019 Ultrasound in Obstetrics and Gynecology

33. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer. (Abstract)

+Foxp-3+ cells, which associated with ARG1 mRNA expression and decreased TNFA in the TU region of the lung of patients with NSCLC as compared to their CTR region. Furthermore, in the CTR region of the lung of patients with NSCLC, CD68+ macrophages were induced and correlated with IL-35+ cells. Finally, IL-35 positively correlated with TTF-1+PD-L1+ cells in the TU region of NSCLC patients.Induced IL-35+Foxp3+ cell numbers in the TU region of the lung of patients with NSCLC associated with ARG1 mRNA (...) expression and with TTF-1+PD-L1+ cells. In the tumour-free CTR area, IL-35 correlated with CD68+ macrophages. Thus inhibitors to IL-35 would probably succeed in combination with antibodies against immune checkpoints like PD-L1 and PD-1 currently used against NSCLC because they would inhibit immunosuppressive macrophages and T regulatory cells while promoting T cell-mediated anti-tumoural immune responses in the microenvironment as well as the TU region of NSCLC patients.

2019 British Journal of Cancer

34. Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. Full Text available with Trip Pro

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for treatment of type 2 diabetes mellitus; however, there have been concerns that GLP-1RA treatment may be associated with an increased incidence of pancreatitis. This study aimed to evaluate the incidence of pancreatitis in a pooled population of type 2 diabetes trials from (...) the clinical development program of the GLP-1RA exenatide as well as to describe patient-level data for all reported cases.The primary analysis examined pooled data among patients with type 2 diabetes from the controlled arms of 35 trials (ranging from 4 to 234 weeks' duration) in the integrated clinical databases for exenatide twice daily, once weekly, and once-weekly suspension, excluding comparator arms with other incretin-based therapies. The exposure-adjusted incidence rate (EAIR) of pancreatitis

2019 Diabetes therapy : research, treatment and education of diabetes and related disorders Controlled trial quality: uncertain

35. One Anastomosis Gastric Bypass/Minigastric Bypass in Patients with BMI &lt; 35 kg/m<sup>2</sup> and Type 2 Diabetes Mellitus: Preliminary Report. (Abstract)

One Anastomosis Gastric Bypass/Minigastric Bypass in Patients with BMI < 35 kg/m2 and Type 2 Diabetes Mellitus: Preliminary Report. Obesity in the world has been increasing, and the number of diabetic patients will increase by 114%, and the best treatment results are achieved through surgery. Several techniques have been described; the gastric bypass of an anastomosis (MGB/OAGB) has been gaining popularity for its simplicity and good results. We present a prospective study (...) with this technique in 16 mild obesity patients with type 2 diabetes mellitus or peripheral insulin resistance.To evaluate weight loss as well as metabolic changes by measuring fasting glycemia and Hb A1c after 1 year of follow-up.Sixteen patients were operated on with the OAGB/MGB technique from September 2014 to January 2016, with some form of metabolic syndrome, whether DM2, RPI, HBP, or dyslipidemia, including patients in the study with a follow-up of at least 12 months.There were 13 cases of female sex and 3

2019 Obesity Surgery

36. Providence nighttime bracing is effective in treatment for adolescent idiopathic scoliosis even in curves larger than 35°. (Abstract)

Providence nighttime bracing is effective in treatment for adolescent idiopathic scoliosis even in curves larger than 35°. Since 2006, the Providence nighttime brace has been used for a conservative treatment for scoliosis. Previous studies comparing the outcomes after full-time bracing and nighttime bracing have reported a comparable outcome with curves < 35°. The aim of this study was to report the outcome after treatment in a cohort of adolescent idiopathic scoliosis patients, with curves (...) and twenty-four patients were included; 80 patients terminated brace treatment and were available for follow-up. Mean in-brace correction was 82%, and curve progression was observed in 9 patients. Brace treatment was success full in 89% of the patients, 88% of the patients braced with curves 20°-29°, 93% of the patients braced with 30°-39° and 77% of the patients braced with curves 40°-45°. Five of the 80 AIS patients were referred to surgery: 4 due to progression and 1 due to cosmetic

2019 European Spine Journal

37. Surgical repair of cervical aortic arch: An alternative classification scheme based on experience in 35 patients. (Abstract)

Surgical repair of cervical aortic arch: An alternative classification scheme based on experience in 35 patients. Cervical aortic arch (CAA) is rare and difficult to repair. Clinical experience is limited. We report the surgical techniques and midterm outcomes in 35 patients with CAA based on an alternative classification scheme.Of 35 patients with CAA, 30 (85.7%) had left-sided aortic arch and 5 had (14.3%) right-sided aortic arch (all 5 had a vascular ring). Mean age was 34.2 ± 13.1 years, 23 (...) -sided aortic arch group, ascending-to-descending aortic bypass was done via median sternotomy in 2 patients and right thoracotomy in 1, and distal arch and descending thoracic aortic replacement via right thoracotomy in 2 patients.Neither death nor spinal cord injury occurred. Left recurrent laryngeal nerve injury, prolonged ventilation, and reexploration for bleeding occurred in 1 each. In 11 patients with coarctation, the upper-lower limb gradient decreased significantly postoperatively (from 34.0

2019 Journal of Thoracic and Cardiovascular Surgery

38. Increasing knowledge in <i>IGF1R</i> defects: lessons from 35 new patients. Full Text available with Trip Pro

Increasing knowledge in IGF1R defects: lessons from 35 new patients. The type 1 insulin-like growth factor receptor (IGF1R) is a keystone of fetal growth regulation by mediating the effects of IGF-I and IGF-II. Recently, a cohort of patients carrying an IGF1R defect was described, from which a clinical score was established for diagnosis. We assessed this score in a large cohort of patients with identified IGF1R defects, as no external validation was available. Furthermore, we aimed (...) to develop a functional test to allow the classification of variants of unknown significance (VUS) in vitro.DNA was tested for either deletions or single nucleotide variant (SNV) and the phosphorylation of downstream pathways studied after stimulation with IGF-I by western blot analysis of fibroblast of nine patients.We detected 21 IGF1R defects in 35 patients, including 8 deletions and 10 heterozygous, 1 homozygous and 1 compound-heterozygous SNVs. The main clinical characteristics of these patients

2019 Journal of Medical Genetics

39. Short-Term Outcomes of Sleeve Gastrectomy plus Jejunojejunal Bypass: a Retrospective Comparative Study with Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in Chinese Patients with BMI ≥ 35 kg/m<sup>2</sup>. (Abstract)

Short-Term Outcomes of Sleeve Gastrectomy plus Jejunojejunal Bypass: a Retrospective Comparative Study with Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in Chinese Patients with BMI ≥ 35 kg/m2. Bariatric surgery represents the most effective treatment for obesity and its related comorbidities. The present study aims to evaluate the efficacy and safety of sleeve gastrectomy plus jejunojejunal bypass (SG + JJB).This retrospective study included 244 obese patients with BMI ≥ 35 kg/m2 (...) undergoing SG + JJB (n = 83), SG (n = 82), and Roux-en-Y gastric bypass (RYGB) (n = 79). Postoperative weight loss, metabolic outcomes, nutrition status, and patients' complaints at 1-year follow-up were compared. Subgroup analyses (36 pairs of SG + JJB/SG and 37 pairs of SG + JJB/RYGB) were performed to compare weight loss and lipid profiles after matching with gender, age, and BMI.In subgroup case-matched study, SG + JJB exhibited superior weight loss effect to SG regarding total weight loss (38.8

2019 Obesity Surgery

40. Prediction of small for gestational age neonates: Screening by maternal factors, fetal biometry and biomarkers at 35-37 weeks' gestation. Full Text available with Trip Pro

Prediction of small for gestational age neonates: Screening by maternal factors, fetal biometry and biomarkers at 35-37 weeks' gestation. Small for gestational age (SGA) neonates are at increased risk for perinatal mortality and morbidity; however, the risks can be substantially reduced if the condition is identified prenatally, because in such cases close monitoring and appropriate timing of delivery and prompt neonatal care can be undertaken. The traditional approach of identifying (...) at 36 weeks' gestation is more effective than that at 32 weeks in predicting birth of SGA neonates.To investigate the potential value of maternal characteristics and medical history, sonographically estimated fetal weight (EFW) and biomarkers of impaired placentation at 35+0- 36+6 weeks' gestation in the prediction of delivery of SGA neonates.A dataset of 19,209 singleton pregnancies undergoing screening at 35+0-36+6 weeks' gestation was divided into a training set and a validation set. The training

2019 American Journal of Obstetrics and Gynecology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>